Throwback to SABCS 2024: Dr. Matteo Lambertini on Risk-Reducing Surgery in Young BRCA Carriers

Throwback to SABCS 2024: Dr. Matteo Lambertini on Risk-Reducing Surgery in Young BRCA Carriers

At SABCS 2024, Dr. Matteo Lambertini shared insights from a major international study examining the role of risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO) in young BRCA carriers with breast cancer. The study, which analyzed data from 5,290 patients across 109 centers worldwide, offers a deeper understanding of how these surgeries impact long-term survival.
Throwback to SABCS 2024: Dr. Icro Meattini on the EUROPA Trial – Optimizing Treatment for Older Women with Early Breast Cancer

Throwback to SABCS 2024: Dr. Icro Meattini on the EUROPA Trial – Optimizing Treatment for Older Women with Early Breast Cancer

At SABCS 2024, Dr. Icro Meattini presented a preplanned interim analysis of the EUROPA trial, a randomized phase III study comparing exclusive endocrine therapy (ET) vs. radiation therapy (RT) in women aged 70+ with luminal-like early breast cancer. The study aimed to evaluate quality of life (HRQOL) and ipsilateral breast tumor recurrence (IBTR) to guide treatment decisions in this patient population.
Throwback to SABCS 2024: Dr. Mafalda Oliveira on HER3-DXd in High-Risk HR+/HER2- Early Breast Cancer

Throwback to SABCS 2024: Dr. Mafalda Oliveira on HER3-DXd in High-Risk HR+/HER2- Early Breast Cancer

Throwback to SABCS 2024, where Dr. Mafalda Oliveira presented findings from the SOLTI VALENTINE phase II trial, evaluating HER3-DXd alone or in combination with letrozole as a neoadjuvant treatment for high-risk HR+/HER2-negative early breast cancer (EBC). The study explored whether HER3-DXd could serve as an effective and tolerable alternative to standard multi-agent chemotherapy.
Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Annual Review | Dr. Jun Guo: Advances in Systemic Therapy for Melanoma in 2024

Malignant melanocytes can appear in various tissues throughout the body, most commonly in the skin and mucous membranes, and are highly aggressive. With continuous advancements in targeted therapy, immunotherapy, and biological therapy, even advanced melanoma can, in many cases, be managed as a chronic disease. Looking back at 2024, what were the key research developments and treatment strategies in systemic therapy for melanoma? Oncology Frontier invited Dr. Jun Guo, Vice President of the Chinese Society of Clinical Oncology (CSCO) and professor at Peking University Cancer Hospital, to provide an expert review and summary. From Professor Guo’s annual analysis, it is evident that numerous novel treatment strategies have already begun or are poised to impact clinical practice, including some pioneering approaches originating from China.